This CEO Is Using Clever Chemistry To Disrupt The Prescription Drug Market. Ensysce Biosciences $ENSC

Guest:


Dr. Lynn Kirkpatrick Chief Executive Officer, Ensysce Biosciences
Inc.


Ticker: $ENSC (NASDAQ)





Website:


https://ensysce.com/





Bio:


Dr. Lynn Kirkpatrick


Chief Executive Officer, Ensysce Biosciences Inc.


Dr. Kirkpatrick has focused her entire career on drug discovery
and development. Former Professor of Chemistry and Biochemistry
in Canada, she has been active in both the novel drug discovery
as well as clinical development of drug candidates throughout her
career. She co-founded three start-up companies and successfully
brought three novel cancer drug candidates and two other drug
candidates in pain and infectious diseases from bench into human
clinical trials.





Following the acquisition of the first company she co-founded,
ProlX Pharmaceuticals, she became President and CEO of Ensysce
Biosciences Inc. and took the company public in 2021. Now Dr.
Kirkpatrick is guiding the clinical development of Ensysce’s
highly novel pain products, which use compelling chemical
approaches to reduce abuse and overdose potential. Dr.
Kirkpatrick received her PhD in Medicinal Chemistry from the
University of Saskatchewan and completed a post-doctoral
fellowship in Pharmacology at Yale University School of Medicine
before returning to Canada where she spent 16 years in academia.





She has published extensively in the area of targeted cancer drug
discovery and development and holds numerous patents for novel
drug candidates.





Company Bio:


Ensysce Biosciences is developing first-in-class and uniquely
innovative solutions in oral drug delivery. Our proprietary TAAP
and MPAR technologies improve the care and safety of patients by
preventing the possibility of both abuse and overdose of
prescription drugs. Our mission is to revolutionize the safety
and oral delivery of medicines for areas of high unmet need.